Leaflet Specials

Fifty percent of India’s citizens remain at the mercy of markets when it comes to healthcare, even as the Indian government remains far behind its goal to commit 2.5 percent of GDP to public health by 2025. A deep-dive into India’s health budget reveals systemic cracks.

In January 2025, the Trump administration's reversal of PEPFAR and USAID funding sent shockwaves across sub-Saharan Africa. From surging infections to abandoned human rights-based care, the consequences, and the complicity, demand a reckoning.

As AI reshapes health systems worldwide, governance must be grounded in human rights norms to avoid reinforcing inequalities and exclusions that have long defined healthcare.

India's rare disease policy sets a Rs. 50 lakh ceiling. Roche's Risdiplam costs Rs. 72 lakhs a year. A generic alternative exists at a fraction of the price, but is tied up in patent litigation. Amidst this, rare disease patients are left to fight their own battles.

What would it take for women to not merely enter Indian law, but to govern it? To sit on the bodies that set its rules, shape its culture, and decide who belongs?

In 2021, only 9 of 441 elected representatives across India's State Bar Councils were women. So women advocates did what they knew best; they went to Court.

For over a decade since the POSH Act’s enactment, women lawyers across the country have remained unaccounted; yet within the structure of the law, there is much the government and the Bar Council of India can do.